Agrin and LRP4 antibodies as new biomarkers of myasthenia gravis

Min Yan, Guang Lin Xing, Wen Cheng Xiong, Lin Mei

Research output: Contribution to journalReview article

  • 2 Citations

Abstract

Myasthenia gravis (MG) is a common disorder that affects the neuromuscular junction. It is caused by antibodies against acetylcholine receptor and muscle-specific tyrosine kinase; however, some MG patients do not have antibodies against either of the proteins. Recent studies have revealed antibodies against agrin and its receptor LRP4—both critical for neuromuscular junction formation and maintenance—in MG patients from various populations. Results from experimental autoimmune MG animal models indicate that anti-LRP4 antibodies are causal to MG. Clinical studies have begun to reveal the significance of the new biomarkers. With their identification, MG appears to be a complex disease entity that can be classified into different subtypes with different etiology, each with unique symptoms. Future systematic studies of large cohorts of well-diagnosed MG patients are needed to determine whether each subtype of patients would respond to different therapeutic strategies. Results should contribute to the goal of precision medicine for MG patients. Anti-agrin and anti-LRP4 antibodies are also detectable in some patients with amyotrophic lateral sclerosis or Lou Gehrig's disease; however, whether they are a cause or response to the disorder remains unclear.

LanguageEnglish (US)
Pages126-135
Number of pages10
JournalAnnals of the New York Academy of Sciences
Volume1413
Issue number1
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Agrin
Myasthenia Gravis
Biomarkers
Antibodies
Amyotrophic Lateral Sclerosis
Anti-Idiotypic Antibodies
Neuromuscular Junction Diseases
Autoimmune Experimental Myasthenia Gravis
Cholinergic Receptors
Protein-Tyrosine Kinases
Medicine
Precision Medicine
Muscle
Neuromuscular Junction
Animals
Cohort Studies
Animal Models
Maintenance
Muscles
Proteins

Keywords

  • agrin
  • LRP4
  • MuSK
  • myasthenia gravis
  • neuromuscular junction

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Agrin and LRP4 antibodies as new biomarkers of myasthenia gravis. / Yan, Min; Xing, Guang Lin; Xiong, Wen Cheng; Mei, Lin.

In: Annals of the New York Academy of Sciences, Vol. 1413, No. 1, 01.01.2018, p. 126-135.

Research output: Contribution to journalReview article

Yan, Min ; Xing, Guang Lin ; Xiong, Wen Cheng ; Mei, Lin. / Agrin and LRP4 antibodies as new biomarkers of myasthenia gravis. In: Annals of the New York Academy of Sciences. 2018 ; Vol. 1413, No. 1. pp. 126-135.
@article{7fc2384d0aad44a98be8833ed3871cf1,
title = "Agrin and LRP4 antibodies as new biomarkers of myasthenia gravis",
abstract = "Myasthenia gravis (MG) is a common disorder that affects the neuromuscular junction. It is caused by antibodies against acetylcholine receptor and muscle-specific tyrosine kinase; however, some MG patients do not have antibodies against either of the proteins. Recent studies have revealed antibodies against agrin and its receptor LRP4—both critical for neuromuscular junction formation and maintenance—in MG patients from various populations. Results from experimental autoimmune MG animal models indicate that anti-LRP4 antibodies are causal to MG. Clinical studies have begun to reveal the significance of the new biomarkers. With their identification, MG appears to be a complex disease entity that can be classified into different subtypes with different etiology, each with unique symptoms. Future systematic studies of large cohorts of well-diagnosed MG patients are needed to determine whether each subtype of patients would respond to different therapeutic strategies. Results should contribute to the goal of precision medicine for MG patients. Anti-agrin and anti-LRP4 antibodies are also detectable in some patients with amyotrophic lateral sclerosis or Lou Gehrig's disease; however, whether they are a cause or response to the disorder remains unclear.",
keywords = "agrin, LRP4, MuSK, myasthenia gravis, neuromuscular junction",
author = "Min Yan and Xing, {Guang Lin} and Xiong, {Wen Cheng} and Lin Mei",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/nyas.13573",
language = "English (US)",
volume = "1413",
pages = "126--135",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Agrin and LRP4 antibodies as new biomarkers of myasthenia gravis

AU - Yan, Min

AU - Xing, Guang Lin

AU - Xiong, Wen Cheng

AU - Mei, Lin

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Myasthenia gravis (MG) is a common disorder that affects the neuromuscular junction. It is caused by antibodies against acetylcholine receptor and muscle-specific tyrosine kinase; however, some MG patients do not have antibodies against either of the proteins. Recent studies have revealed antibodies against agrin and its receptor LRP4—both critical for neuromuscular junction formation and maintenance—in MG patients from various populations. Results from experimental autoimmune MG animal models indicate that anti-LRP4 antibodies are causal to MG. Clinical studies have begun to reveal the significance of the new biomarkers. With their identification, MG appears to be a complex disease entity that can be classified into different subtypes with different etiology, each with unique symptoms. Future systematic studies of large cohorts of well-diagnosed MG patients are needed to determine whether each subtype of patients would respond to different therapeutic strategies. Results should contribute to the goal of precision medicine for MG patients. Anti-agrin and anti-LRP4 antibodies are also detectable in some patients with amyotrophic lateral sclerosis or Lou Gehrig's disease; however, whether they are a cause or response to the disorder remains unclear.

AB - Myasthenia gravis (MG) is a common disorder that affects the neuromuscular junction. It is caused by antibodies against acetylcholine receptor and muscle-specific tyrosine kinase; however, some MG patients do not have antibodies against either of the proteins. Recent studies have revealed antibodies against agrin and its receptor LRP4—both critical for neuromuscular junction formation and maintenance—in MG patients from various populations. Results from experimental autoimmune MG animal models indicate that anti-LRP4 antibodies are causal to MG. Clinical studies have begun to reveal the significance of the new biomarkers. With their identification, MG appears to be a complex disease entity that can be classified into different subtypes with different etiology, each with unique symptoms. Future systematic studies of large cohorts of well-diagnosed MG patients are needed to determine whether each subtype of patients would respond to different therapeutic strategies. Results should contribute to the goal of precision medicine for MG patients. Anti-agrin and anti-LRP4 antibodies are also detectable in some patients with amyotrophic lateral sclerosis or Lou Gehrig's disease; however, whether they are a cause or response to the disorder remains unclear.

KW - agrin

KW - LRP4

KW - MuSK

KW - myasthenia gravis

KW - neuromuscular junction

UR - http://www.scopus.com/inward/record.url?scp=85041073423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041073423&partnerID=8YFLogxK

U2 - 10.1111/nyas.13573

DO - 10.1111/nyas.13573

M3 - Review article

VL - 1413

SP - 126

EP - 135

JO - Annals of the New York Academy of Sciences

T2 - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

IS - 1

ER -